期刊文献+

TPF方案诱导化疗对局部N晚期鼻咽癌的近期疗效 被引量:8

Short-term effects of induction chemotherapy with one cycle TPF regimen in the N advanced local nasopharyngeal carcinoma
原文传递
导出
摘要 目的 比较1个疗程TPF方案和2个疗程PF方案作为诱导化疗对局部N晚期鼻咽癌的近期疗效和患者不良反应.方法 收集2007年1月至2008年12月初治的47例接受过诱导化疗的局部N晚期鼻咽癌患者,其中采用1个疗程TPF诱导化疗方案26例,采用2个疗程PF诱导化疗方案21例;唧方案使用多西紫杉醇(Docetaxel,TAX,商品名:泰素帝)60mg/m2,静脉滴注,第1天;顺铂(DDP)80mg/m2,静脉滴注,第1天;5-氟尿嘧啶(5-Fu)800mg/m2,第1天至第4天,静脉泵注.PF方案使用DDP 100 mg/m2,静脉滴注,第1天;5-Fu 1000 mg/m2,第1天至第4天,静脉泵注;两组均为3周方案.随后两组均采用DDP(30 mg/m2,每周方案)单药为基础的同期放化疗.观察比较两组患者的近期疗效和不良反应.结果 试验组诱导化疗后鼻咽部病灶有效率(CR+PR)57.7%;颈部有效率69.2%,对照组2个疗程PF方案诱导化疗后鼻咽部病灶有效率66.7%;颈部有效率71.4%(P>0.05).治疗后3个月试验组鼻咽部病灶和颈部淋巴结CR率分别为92.3%和88.7%,而对照组鼻咽部病灶和颈部淋巴结CR率分别为100.0%和90.5%(P>0.05).试验组治疗不良反应主要是中性粒细胞减少和脱发.结论 1个疗程TPF诱导化疗对局部N晚期鼻咽癌可取得较好的局部控制率,中性粒细胞减少是主要的治疗毒性. Objective To compare the short-term effects and toxicity of one cycle of TPF regimen induction chemotherapy with that of two cycles of PF regimen induction chemotherapy in the N advanced local nasopharyngeal carcinoma (NPC). Methods A total of 47 patients initially treated with N advanced local NPC without distant metastasis from Jan 2007 to Dec 2008 were enrolled in this study. The TPF chemotherapy regimen was administered as follows: TAX 60 mg/m2, i.v. infusion on day 1st, cisplatin 80 mg/m2, i.v. infusion on day 1st and 5-Fu 800 mg/m2, bolus infusion in 96 hours on day lst-4th. The PF chemotherapy regimen was as follows: cisplatin 100 mg/m2, i.v. infusion on day 1 and 5-Fu 1000 mg/m2, bolus infusion in 96 hours on day lst-4th. Twenty-six patients received one cycle of TPF regimen and 21 patients received two cycles of PF regimen, with 21 days each cycle and a total of 3 courses in each group, then chemoradiotherapy with cisplatin 30 mg/m2 (weekly) was followed. Results The short-term efficacy was no significant difference between two groups, after one cycle TPF chemotherapy, the CR+PR rates of primary site and lymph nodes were 57.7 % and 69.2 %, respectively, while after two cycles PF chemotherapy in control group, those were 66.7 % and 71.4 %, respectively (P〉0.05). In 3 months after treatment, the CR rates of primary site and lymph nodes in TPF group were 92.3 % and 88.7 %, respectively, while those in control group were 100.0 % and 90.5 %, respectively (P〉0.05). The main adverse reactions were Grade Ⅲ-Ⅳ neutropenia and alopecia in TPF group. Conclusion Short-term effects of induction chemotherapy with one cycle of TPF regimen in the N advanced local NPC is satisfied, and the main toxicity is neutropenia.
出处 《肿瘤研究与临床》 CAS 2010年第8期512-514,共3页 Cancer Research and Clinic
关键词 鼻咽肿瘤 多西紫杉醇 顺铂 5-氟尿嘧啶 诱导化疗 Nasopharyngeal neoplasms Docetaxel Cisplatin Fluorouracil Induction chemoradiotherapy
  • 相关文献

参考文献8

  • 1Schrijvers D,Van Herpen C,Kerger J,et al.Docetaxel,cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer A phase I-II feasibility study.Ann Oncol,2004,15:638-645.
  • 2Posner M,Glisson B,Frenette G,et al.Multieenter phase Ⅰ-Ⅱ trial of docetaxel,cisplatin,and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.J Clin Oncol,2001,19:1096-1104.
  • 3马骏,麦海强,莫浩元,卢泰祥,崔念基,洪明晃.鼻咽癌放射治疗失败原因分析[J].癌症,2000,19(11):1016-1018. 被引量:134
  • 4吴少雄,赵充,崔念基,卢泰祥,邓美玲,黄莹.诱导化疗在局部晚期鼻咽癌放射治疗中的价值[J].肿瘤防治杂志,2004,11(12):1289-1292. 被引量:12
  • 5Vermorken JB,Remenar E,van Herpen C,et al.Cisplatin,fluorouracil,and docetaxel in unresectable head and neck cancer.N Engl J Med,2007,357:1695-1704.
  • 6Posner MR,Hershock DM,Blajman CR,et al.Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.N Engl J Med,2007,357:1705-1715.
  • 7Hui EP,Ma BB,Leung SF,et al.Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma.J Clin Oncol,2009,27:242-249.
  • 8吕星,郭翔,洪明晃,陈秋燕,曾奇,向燕群.多西紫杉醇联合卡铂与氟尿嘧啶联合卡铂治疗局部晚期鼻咽癌近期疗效的比较[J].癌症,2010,29(2):148-152. 被引量:14

二级参考文献43

  • 1罗伟,张恩罴,涂明耻,毛志达,曾祥发.改进鼻咽癌放射治疗技术的研究—(Ⅱ)临床近期疗效[J].癌症,1996,15(4):280-282. 被引量:21
  • 2AI-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase Ⅲ randomized Intergroup study 0099 [J]. J Clin Oncol, 1998,16(4) : 1310-1317.
  • 3Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study [J]. J Clin Oncol, 2004,22(13):2643-2653.
  • 4Ogawa T, Terada A, Hyodo I, et al. A Phase Ⅰ study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head and neck [J]. Gan To Kagaku Ryoho, 2005,32 (7) :977-981.
  • 5Chan AT, Ma BB, Lo YM, et al. Phase Ⅱ study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA [J]. J Clin Oncol, 2004,22 (15) : 3053-3060.
  • 6Baujat B, Bourhis J, Chan AT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients [J]. Int J Radiat Oncol Biol Phys, 2006,64:47-56.
  • 7Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature [J]. J Clin Oncol, 2004,22(22):4604-4612.
  • 8Nabell L, Spencer S. Docetaxel with concurent radiotherapy in head and neck cancer [J]. Semin Oncol, 2003,30(6 Suppl 18):89-93.
  • 9Hehr T, Classen J, Belka C, et al. Radiation alternating with docetaxel and cisplatin in inoperable recurence of head and neck cancer: a prospective phase Ⅰ/Ⅱ trial [J]. Int J Radiat Oncol Biol Phys, 2005,61 (5) : 1423-1431.
  • 10Hui EP, Ma BB, Leung SF, et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma [J]. J Clin Oncol, 2009,27(2):242-249.

共引文献157

同被引文献88

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部